BRET CORNN: Open Payments
NPI 1730105768 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$638 in 42 payments from 16 companies in 2025. Trend: 2023 $1,305 · 2024 $880 · 2025 $638
Food & beverage: $638
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $164 |
| Lilly USA, LLC | 5 | $83 |
| PFIZER INC. | 4 | $70 |
| Abbott Laboratories | 2 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| Novo Nordisk Inc | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
Products named: VRAYLAR, JARDIANCE, MOUNJARO, PROCLAIM, QULIPTA, NURTEC ODT, LEQVIO, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
